The transcription factors Adr1 and Cat8 act in concert to regulate the expression of numerous yeast genes after the diauxic shift. Their activities are regulated by Snf1, the yeast homolog of the AMP-activated protein kinase (AMPK) of higher eukaryotes. Cat8 is regulated directly by Snf1, but how Snf1 regulates Adr1 is unknown. Mutations in Adr1 that alleviate glucose repression are clustered between amino acids 227 and 239. This region contains a consensus sequence for protein kinase A, RRAS 230 F, and Ser230 is phosphorylated in vitro by both protein kinase A and Ca ++ -calmodulin-dependent protein kinase. Using an antiphosphopeptide antibody, we found that the level of Adr1 phosphorylated on Ser230 was highest in glucose-grown cells and decreased in a Snf1-dependent manner when glucose was depleted. A non-phosphorylatable Ser230Ala mutant was no longer Snf1-dependent for activation of Adr1-dependent genes and could suppress Cat8-dependence at genes co-regulated by Adr1 and Cat8.
Introduction
Transcription factors activate gene expression by recruiting coactivators to a promoter to create a pre-initiation complex (PIC) containing RNA polII and general factors (FEATHERSTONE 2002; FRY and PETERSON 2002) . Signal transduction pathways often regulate this process by acetylation or phosphorylation of transcription factors to influence their ability to recruit coactivators (GOEL and JANKNECHT 2003; KWOK et al. 1994; PAPOUTSOPOULOU and JANKNECHT 2000; ZHONG et al. 2002) . Adr1 is a yeast transcription factor that acts in concert with Cat8 and Oaf1/Pip2 to activate numerous genes that are expressed after glucose depletion, allowing cells to use non-fermentable carbon sources such as ethanol, glycerol, and fatty acids (SANTANGELO 2006; SCHULLER 2003; YOUNG et al. 2003) . The signal transduction pathway that activates Adr1 and Cat8 is mediated by Snf1 (CHARBON et al. 2004; RAHNER et al. 1999; SANTANGELO 2006; SCHULLER 2003) , the yeast homolog of AMP-activated protein kinase (AMPK) that is widely regarded as the "energy sensor of the cell" (HARDIE et al. 1998) . Snf1 is activated by phosphorylation on Thr210 by three upstream kinases (HONG et al. 2003) . Snf1-Thr210 is dephosphorylated by the PP1-type protein phosphatase Glc7, and regulation of this event appears to be through the targeting factor Reg1 (RUBENSTEIN et al. 2008; SANZ et al. 2000) . As expected, removing the negative regulatory mechanism by deleting REG1 causes constitutive activation of Snf1, as measured by expression in glucose of Snf1-dependent genes that are normally glucose-repressed (Dombek et al. 1993; (MCCARTNEY and SCHMIDT 2001; ORLOVA et al. 2008; TU and CARLSON 1995) . Control of Snf1 must include additional mechanisms beyond simple phosphorylation and Glc7•Reg1-dependent dephosphorylation, however, because in a reg1∆ strain, additional phosphorylation of Snf1 and further activation of some Snf1-dependent genes is achieved by glucose depletion (DOMBEK et al. 1993; ORLOVA et al. 2008; TACHIBANA et al. 2007) . Interaction with regulatory proteins or changes in protein structure have been suggested as additional levels of Snf1 control (RUBENSTEIN et al. 2008) .
Snf1 is necessary for the activity of both Adr1 and Cat8, enhancing transcription of CAT8 through inactivation of the repressor Mig1, as well as activating Cat8 directly by phosphoryation ((CHARBON et al. 2004; HEDGES et al. 1995; RAHNER et al. 1999; RAHNER et al. 1996) ; reviewed in (SCHULLER 2003) ). Snf1 is required for Adr1 binding (YOUNG et al. 2002) and recruitment of coactivators to Adr1-dependent promoters (BIDDICK et al. 2008) . Promoter binding by Adr1 is regulated in part by phosphorylation of its DNA binding domain (KACHEROVSKY et al. 2008) and by acetylation of promoter nucleosomes (TACHIBANA et al. 2007; VERDONE et al. 2002) , but it is not known whether Snf1 activates Adr1 directly or indirectly, or has another role at Adr1-dependent promoters, such as nucleosome modification (LO et al. 2001) .
Selection of mutants that allowed ADH2 expression to escape glucose repression identified rare semi-dominant ADR1 c alleles (ADR1-constitutive) (CIRIACY 1979; DENIS et al. 1991) . ADR1 c alleles allow ADH2 expression to occur in the presence of glucose and enhance derepressed transcription. Surprisingly, the level of Adr1 c protein is much lower than the level of wildtype Adr1 (DOMBEK 1997; TAYLOR and YOUNG 1990) , suggesting that its high transcriptional potency might be associated with rapid turnover as has been observed for some other activators (TANSEY 2001) . ADR1 c shows strong synergism with deletion of the Snf1 regulatory factor REG1. In combination with Adr1 c , partial activation of Snf1 by deleting REG1 allows much higher levels of ADH2 repressed expression than are observed with either mutation acting alone (DOMBEK et al. 1993) . Adr1 c and reg1∆ are also synergistic in activating a poised but inactive PIC (TACHIBANA et al. 2007) . Although this suggests that Adr1 c and activation of Snf1 by reg1∆ act through different pathways to cause constitutive expression of Snf1-dependent genes, the precise mechanism of the synergism is unknown.
Cloning and molecular analysis of ADR1 c alleles showed mutations between amino acids 227 and 239, a region that contains a consensus sequence for a cyclic AMP-dependent protein kinase (PKA), Arg-Arg-Ala-Ser-Phe (DENIS et al. 1992; DENIS and GALLO 1986) . No other mutations in the Adr1 ORF causing constitutive ADH2 expression were isolated, suggesting that the 227-239 region plays a unique role in regulating Adr1 activity. The ADR1 c mutations suggest that Adr1 might be post-translationally inhibited by phosphorylation of Ser230 in the PKA consensus sequence (CHERRY et al. 1989; DENIS and GALLO 1986 ). Adr1 appears to be phosphorylated at Ser230 in vivo because subtle alterations in its SDS-PAGE electrophoretic mobility and partial sensitivity to phosphatase treatment are observed (DOMBEK 1997; VALLARI et al. 1992) . Recent studies of the yeast phosphorylome also suggested Adr1 phosphorylation, although the reported site was Ser232, not Ser230 (CHI et al. 2007) .
In support of phosphorylation of Adr1 by PKA, both PKA and calmodulin-dependent protein kinase (CMK) efficiently phosphorylate Ser230 in vitro (DENIS et al. 1991; HOOK et al. 1999 ). Hyperactivation of PKA by deletion of its BCY1-encoded regulatory subunit causes loss of ADH2 expression (CHERRY et al. 1989) , suggesting that unregulated PKA activity inhibits Adr1 by constitutively phosphorylating Ser230. However, replacing Ser230 with phosphomimetic Asp gave the same constitutively active phenotype as other alterations in the region, suggesting that either Asp does not mimic phosphorylated Ser, or phosphorylation of Ser230 is not the only determinant of the ADR1 c phenotype (DENIS et al. 1992; DOMBEK 1997) . In addition, several of the Adr1 c mutations appear to refute PKA as a candidate for the Ser230 kinase in vivo. The Ala229Pro Adr1 c mutant shows greatly increased affinity for PKA binding in a peptide phosphorylation assay, which would predict greater phosphorylation and lower Adr1 activity.
However, the Ala229Pro mutant is one of the most constitutive of the Adr1 c mutants (DENIS et al. 1992) . Therefore, it is not known if phosphorylation of Ser230 affects the activity of Adr1, and what kinase is responsible for the phosphorylation in vivo (COOK et al. 1994; DENIS et al. 1992; DOMBEK 1997) .
How Adr1 c achieves its high transcriptional potency is unknown (COOK et al. 1994; DENIS et al. 1992; DOMBEK 1997) . ADR1 c alleles map far from the DNA binding domain and Adr1-Ser230A does not have enhanced in vitro DNA binding activity (TAYLOR and YOUNG 1990) . After characterizing a series of mutants in amino acids 227-239, as well as internal deletions in this region of Adr1, Cook (COOK et al. 1994; DENIS et al. 1992; DOMBEK 1997) suggested this region either binds a repressive factor that cannot interact with the mutants or interacts with and blocks the activation domain. Some evidence has suggested that these Adr1 c mutants suppress the requirement for Snf1 (CIRIACY 1979; DENIS 1984) , which would imply it is not affected by Snf1, but this is contradictory to the enhanced effect on ADH2 expression seen when Adr1 c is combined with the Snf1-activating reg1∆ mutation. Thus, the question of how Snf1 affects the activity of Adr1, and whether it interacts with the Adr1 c allele is unresolved.
We used an antibody against a Ser230-phosphorylated peptide of Adr1 amino acids 217-234 to investigate the conditions under which Ser230 is phosphorylated (Adr1-pSer230), and the effect of Snf1 on this modification. The antibody was used to screen for a specific Adr1-Ser230 Knop et al., Cross, and Guldener et al. (CROSS 1997; GULDENER et al. 1996; KNOP et al. 1999) , respectively. Deletions and epitope tagging were confirmed by PCR and, for the latter, by
Western blots. Yeast strains were grown in complete or synthetic media as described in Sherman (SHERMAN 1991) . Repressing medium contained 5% glucose; derepressing medium contained 0.05% glucose with or without 3% glycerol or 2% ethanol. The plasmids used were described previously (DOMBEK 1997; YU et al. 1989 ) modified in some cases by introducing an epitope tag at the C-terminus of Adr1 as described below. For gene expression studies CEN-TRP1 plasmids expressing either wild-type ADR1 (pKD16) or the S230A (pKD14), R228K (pKD27), or Δ3 (a deletion that removes Adr1 amino acids 226-233; pKD26) alleles of ADR1 from its native promoter were used. To facilitate detection of Adr1-S230 phosphorylation by western blotting 2µ plasmids expressing wild-type ADR1 (pKD17-HA::kanMX (TRP1) and the ADR1-S230A allele (pKD20-HA::kanMX (TRP1) from the ADH1 promoter and tagged with an HA-epitope were employed. Alternatively, strains with four additional copies of ADR1 integrated at the leu2 locus were used (SLOAN et al. 1999) . ADR1 was epitope tagged with HA::kanMX in this strain. The Adr1-dependent reporter was a UAS1-lacZ plasmid, pHDY10, containing ten Adr1 binding sites (YU et al. 1989) . Enzyme assays -β-Galactosidase assays were performed as described in Guarente (GUARENTE 1983) . ADH enzyme activity was analyzed by separating proteins on nondenaturing polyacrylamide gels and visualized by in-gel chromogenic staining as described (DOMBEK 1997) .
Real-time Quantitative PCR (RT-qPCR):
For expression analysis, RNA was isolated by hot phenol extraction (COLLART and OLIVEIRO 1993) and converted to cDNA with a SuperScript III kit (Invitrogen) according to the manufacturer's directions. cDNA were quantified by RT-qPCR (TACHIBANA et al. 2007 ) with an MJ Research Chromo4 system, using ABI or Quantace SYBR Master Mix, according to the manufacturers' instructions. Primer sequences are available on request.
Immunoblotting: Whole cell extracts were analyzed on 3-8% or 6% polyacrylamide gels (NuPage system, Invitrogen) and transferred to PVDF membranes after electrophoresis. Western blots were probed with α-pSer230 followed by a rabbit-specific Licor secondary Ab (l680). A second identical blot was probed with a monoclonal α-HA antibody and a mouse-specific Licor secondary antibody (l800). Probing a single blot with both antibodies resulted in bleed-through from the more abundant HA epitope-derived signal so either two blots were done or a single blot was probed sequentially, first with α-pSer230 and an appropriate Licor secondary antibody and second with the α-HA antibody and an appropriate Licor secondary antibody. Cell extracts were prepared as described previously (DOMBEK 1997) antibodies against an Adr1-derived synthetic peptide were used at 1:1000 dilution. The peptides, representing Adr1 amino acids 217-234, VKRKYLKKLTRRA(pS)FSAQ, and its nonphosphorylated version were synthesized and used to generate and affinity purify the α-pSer230
antibody by Bethyl Laboratories (Montgomery, TX). Secondary IR-dye conjugated antibodies used at 1:1000 -1:3000 were goat α-mouse Alexa 680 (Molecular Probes) or IRdye800 conjugated α-rabbit IgG (Rockland Immunochemicals).
RESULTS

Adr1-Ser230 phosphorylation in vivo is glucose-dependent and dephosphorylation is Snf1-dependent
Antibodies against a phosphorylated peptide representing Adr1 amino acids 217-234
(VKRKYLKKLTRRA(pS)FSAQ) were generated to assess the level of Adr1 phosphorylated on Ser230 in vivo (designated Adr1-pSer230). ELISA assays indicated that the anti-phosphopeptide antibody (α-pSer230) recognized the phosphorylated peptide 5000-times better than the nonphosphorylated peptide (data not shown). Figure 1A shows that α-pSer230 recognized a protein the size of Adr1 in a strain expressing Adr1-HA from the strong ADH1 promoter on a multicopy plasmid, but not in a strain lacking Adr1. Adr1 containing a Ser230Ala mutation (hereafter referred to as Adr1 c unless other ADR1 c alleles are specified) was recognized poorly by α-pSer230, demonstrating the specificity of the antibody for Adr1 with phosphorylated Ser230.
Competition with the phosphorylated and non-phosphorylated peptides demonstrated the specificity of α-pSer230 ( Figure 1B ). These data confirmed that α-pSer230 recognized Adr1-pSer230 and cross-reacted weakly, if at all, with Adr1 lacking phosphate on Ser230.
A strain containing multiple integrated copies of ADR1 was employed to facilitate quantitation of Adr1-pSer230 in different growth conditions. At least one copy of Adr1 in this strain was tagged with an HA epitope to provide a measure of the total amount of Adr1 in the extract. Adr1 levels in the multicopy strain grown in repressing conditions are similar to Adr1 levels in wildtype cells grown in derepressing conditions, and ADH2 regulation appears unperturbed by the modest increase in Adr1 levels (SLOAN et al. 1999; VORONKOVA et al. 2006) .
Western blotting for both HA and Adr1-pSer230 revealed that the amount of pSer230 relative to total Adr1 was highest in glucose-grown cells and decreased about 10--fold when cells were grown in low glucose plus ethanol ( A strain lacking SNF1 is unable to activate ADH2 expression presumably due to inactive Adr1. Consistent with the hypothesis that phosphorylation of Ser230 inactivates Adr1, in a snf1Δ strain, the amount of Adr1-pSer230 relative to total Adr1 appeared to be elevated in the presence of glucose and did not decrease significantly after its removal ( Figure 2A , middle two lanes).
Since Snf1 is a kinase, any regulation of phosphorylated Ser230 must be indirect, for example through control of another kinase or a phosphatase. Surprisingly, although dephosphorylation of Ser230 appeared to be Snf1-dependent, deleting REG1 or inactivating GLC7 with a ts mutation to activate Snf1 in repressing conditions did not affect the relative level of Adr1-pSer230 in either repressing or derepressing conditions ( Figure 2A , right 2 lanes and unpublished data for Glc7-127). The experiment was repeated multiple times with similar results. Snf1 control of Adr1-pSer230 apparently requires additional levels of Snf1 regulation, such as control over access to the Snf1 T210 phosphorylation site, that work with dephosphorylation by Reg1•Glc7 to mediate Snf1 activity (ORLOVA et al. 2008; RUBENSTEIN et al. 2008) . Alternatively, Ser230 dephosphorylation in glucose may be prevented by a mechanism that is independent of Reg1•Glc7. In summary, inactivation of Snf1 prevented the decrease in Ser230 phosphorylation that normally accompanies derepression and activation of Adr1-dependent genes, consistent with phosphorylation playing a negative role in regulating the activity of Adr1.
The stoichiometry of phosphorylation on Ser230 was assessed by immunoprecipitation of Adr1 in whole cell extracts derived from the multicopy ADR1 strain grown in repressing conditions. Adr1 was quantitatively immune-precipitated with α -Adr1 and α-pSer230 antisera and the precipitated and supernatant fractions were analyzed by SDS-PAGE. Western blotting using α-Adr1 antisera, which recognizes both phosphorylated and non-phosphorylated Adr1 demonstrated that α-Adr1 and α-pSer230 antisera immune-precipitated 65%, and 45%, respectively, of the total Adr1 (Supplementary Figure 1) . Dephosphorylation of pSer230 during immune-precipitation may contribute to the lower level of Adr1 immune-precipitated by the α-pSer230 antisera compared to the α-Adr1 antisera or there may be a fraction of Adr1 that is not phosphorylated on Ser230 even in repressing growth conditions. The high level of Adr1 precipitated by the α-pSer230 antisera indicates that the majority of Adr1 is phosphorylated in vivo in repressing conditions.
Adr1 c activation is Snf1-independent; synergism with reg1∆ is from Snf1 activation of Cat8
Since the decrease of Adr1-Ser230 phosphorylation did not occur in a snf1∆ strain, we hypothesized that if this decrease were important for the activity of Adr1, Adr1 c , which has the phosphorylatable serine mutated to alanine, would be insensitive to snf1∆. As predicted, both ADH2/lacZ reporter assays and in-gel assays of endogenous ADHII activity showed that Adr1 c was highly efficient at activating ADH2, even in the absence of Snf1. ADH2 derepression by Adr1 c was reduced only four-fold in the snf1 mutant, compared to an almost complete lack of expression with wildtype Adr1 (Supplementary Figure 2) . Snf1-independence of Adr1 c was also seen when mRNA from ADH2 was measured directly by RT-qPCR. With this assay, we found that other Adr1-dependent genes, including POX1 and SPS19, were also activated in a Snf1-independent manner by Adr1 c . Adr1 c did not change the expression of FBP1, which is not Adr1-dependent ( Figure 3A) . Other Adr1 c variants of the Ser230 region were used to show that the Snf1-independence was a general effect, as two other alleles, Adr1-∆3 (∆(226-223)) and Adr1-R228K, also activated the Adr1-dependent genes without Snf1. The CAT8-dependent FBP1 gene (TACHIBANA et al. 2005; DOMBEK et al. 1993; TACHIBANA et al. 2007) was not derepressed in snf1∆ strains by Adr1 c alleles ( Figure 3B) . ADR1 c could not overcome the Snf1 requirement for growth on the non-fermentable carbon sources ethanol, glycerol, lactate or acetate, however (data not shown). This is unsurprising since Cat8 is essential for growth on these carbon sources and expression of Cat8-dependent genes such as FBP1 were unaffected by Adr1 c . In addition there are other Snf1-dependent transcription factors such as Mig1 that are involved in gene expression for these metabolic pathways.
The lack of Snf1 control over Adr1 c alleles raised a question about earlier results showing synergism between Adr1 c and reg1∆ (DOMBEK et al. 1993; TACHIBANA et al. 2007) , in which Adr1 c -containing strains show additional activation of ADH2 when Snf1 is activated in glucose by reg1∆. Adr1 c was Snf1-independent, so it should not be influenced by reg1∆. A clue to the mechanism of the synergism came from the high Snf1-dependence seen for the Cat8-dependent FBP1 gene (Figure 3A,B) and the lack of synergism seen at Cat8-independent genes like POX1
(data not shown). We hypothesized that the additional activation of ADH2 seen when REG1 was deleted in an Adr1 c -containing strain, is from Snf1 activation of Cat8. If this hypothesis is correct, reducing the Cat8 effect should reduce the synergism. We measured ADH2 activation independently of other activators using a reporter that lacked binding sites for Cat8, and had only the Adr1-binding site (UAS1) of the ADH2 promoter (YU et al. 1989 ). Snf1-dependence and synergism with reg1∆ was determined in strains carrying the reporter, and either wildtype Adr1
or Adr1 c . The activity of the reporter in the REG1 strain with wildtype Adr1 was very low in repressing conditions and increased 260-fold in derepressing conditions ( Table 2 ). The Adr1 c allele showed the expected constitutive activity and hyperactivation. In the reg1∆ mutant, wildtype Adr1 showed constitutive ß-galactosidase activity to about 10% of the 8-hour derepressed value in the REG1 strain. The same degree of constitutive activity was seen when Adr1 c was the activator in the reg1∆ strain, instead of the synergistic effects seen previously in assays that measured expression from the entire ADH2 promoter (DOMBEK et al. 1993; TACHIBANA et al. 2007 ). In the reg1∆ strain, both the wildtype and Adr1 c alleles showed a slight increase in constitutive activity over the REG1 strain, possibly due to the two-to-three-fold elevated ADR1 transcription that is observed in a reg1Δ mutant (DOMBEK et al. 1993) .
We additionally tested the reliance of Adr1 c and reg1∆ synergism on Cat8 by deleting CAT8 in an adr1Δ reg1Δ mutant strain and introducing wildtype Adr1 or Adr1 c on plasmids.
ADH2 expression was measured by isolating mRNA and performing RT-qPCR. The results indicated that Cat8 was required for the high, glucose-resistant ADH2 expression in the reg1Δ strain when either wildtype Adr1 or Adr1 c was the activator (Table 3) . Efficient derepression by Adr1 c was also abolished in the double cat8Δreg1Δ mutant.
Adr1 c partially suppresses Cat8-dependence at genes activated by both Adr1-and Cat8
In addition to showing that Cat8 was required for the constitutivity conferred by reg1∆, the results with the cat8∆ strains indicated that ADH2 expression mediated by Adr1 c in the presence of Reg1 was largely independent of Cat8 ( Figure 3A) and by in-gel staining of ADH activity in cell extracts (Supplementary Figure 3B) . Genes mainly dependent on Cat8 such as FBP1 and ICL1 were unaffected by Adr1 c (Fig. 4) . In summary, Adr1 c efficiently suppressed the Cat8-requirement for numerous genes whose derepression is normally co-dependent on Adr1 and Cat8. These results are consistent with those in the previous section that documented the partial Snf1-independence of Adr1 c .
Protein synthesis is required to regulate Adr1-pSer230 levels
The importance of pSer230 and the Ser230 domain was demonstrated by the activity of Adr1 c , even in low glucose and even without its co-regulator Cat8. To address the mechanism by which Ser230 phosphorylation levels are regulated, we measured phosphorylation levels of Adr1-Ser230, in the absence of protein synthesis. The amount of total and Ser230-phosphorylated Adr1 was determined by Western blotting. In the presence or absence of glucose, after cycloheximide (Cyh) addition, the Adr1-pSer230 and total Adr1 decreased at the same rate, suggesting that Ser230-phosphorylated Adr1 and total Adr1 turn over at the same rate in both repressing and derepressing growth conditions in the absence of protein synthesis (data not shown).
In a more complex experiment diagrammed in 
Screening for the Adr1-Ser230 kinase
A peptide representing the Ser230 region of Adr1 is an efficient substrate in vitro for both PKA (DENIS et al. 1992) and CMK (HOOK et al. 1999) . Early studies suggested that Adr1 was inactivated in vivo by phosphorylation of Ser230 by PKA (CHERRY et al. 1989 ), but genetic analysis was less supportive of this model (DENIS et al. 1992; DOMBEK 1997) . To determine whether Ser230 is phosphorylated in vivo by these protein kinases, we used yeast strains lacking all PKA activity (tpk1Δtpk2Δtpk3Δ yak1Δ and tpk1∆tpk2∆tpk3-ts) or all CMK activity (cmk1Δcmk2Δcmk3Δ). The tpk-null strain was kept viable by deleting YAK1, encoding another protein kinase (GARRETT and BROACH 1989) . This strain showed normal glucose regulation of ADH2 (data not shown), consistent with previous studies with a tpk1Δtpk2Δtpk3-ts mutant (DOMBEK 1997; VALLARI et al. 1992) . The triple cmk-null strain was viable but grew slowly, and its ADH2 regulation was also normal (data not shown). We expected pSer230 to be absent if the mutations eliminated the Ser230 kinase, but phosphorylated Adr1 was clearly detectable in strains lacking either PKA or CMK. The relative level of Adr1-pSer230 compared to total Adr1 was measured by Western blotting in strains containing overexpressed Adr1, and was found to be altered by less than a factor of two, for both the PKA and CMK mutant strains ( Figure 6A ). The 30% reduction in the cmk1-3∆ strain may be a consequence of the partial degradation of Adr1 that occurred in this strain. A similar result was obtained in a tpk1∆tpk2∆tpk3-ts mutant (N.
Kacherovsky, unpublished).
The presence of Adr1 phosphorylated on Ser230 in the tpk-null strain was not due to overexpression. Adr1-pSer230 was also detected in the tpk1-3∆yak∆ strain with single copy Adr1 after immuno-precipitation. The immune precipitates from wt and the quadruple mutant were analyzed by SDS-PAGE and western blotting for Adr1. The Licor secondary antibody revealed a similar amount of Adr1 in both immune precipitates (Supplementary Figure 4) . The low concentration of Adr1-pSer230 in the supernatant fraction precluded its detection.
As a second method of testing for in vivo phosphorylation of pSer230 by PKA, we measured the relative level of Adr1-pSer230 in a strain lacking Bcy1, the regulatory subunit of PKA. The bcy1∆ mutation was introduced into the same multicopy strain used to study pSer230 in the mutants described in Figures 2 and 5 . The total amount of Adr1, as determined by blotting for the HA epitope on Adr1, was lower in the bcy1Δ strain than in the wt parent as expected because constitutive activation of Tpk reduces expression from the ADR1 promoter (Dombek 1994 ). We observed a slow rate of ADH2 derepression, measured by both in situ staining of ADH activity and by reporter assays (Supplementary Figure 5) , most likely because of the lower levels of Adr1. If PKA phosphorylates Ser230 in vivo, we expected to see a significant increase in Adr1-pSer230 in this strain. However, the relative level of Adr1-pSer230 was unaffected in the bcy1∆ mutant ( Figure 6B) .
We considered the possibility that Adr1-pSer230 might already be fully phosphorylated in repressing conditions (Supplementary Figure 1) . If so, the effect of constitutive activation of PKA in the bcy1∆ strain might only be observed in derepressing conditions, when Adr1-pSer230 decreases in the BCY1 parent strain (Figure 2) . However, loss of BCY1 did not increase the relative level of pSer230 in either repressing or derepressing conditions ( Figure 6B and data not shown). This result is unlikely to be a consequence of the reduced level of Adr1 in the bcy1∆ mutant because the level of Adr1 in the multicopy bcy1∆ strain is similar to the level of Adr1 in a single copy ADR1 BCY1 wt strain. Ser230 kinase candidates, overexpression of Adr1 was necessary to quantify the level of Adr1-pSer230. Although we cannot rule out the possibility that non-specific phosphorylation of the overexpressed protein masked identification of the important kinase, the wildtype control with the same plasmid did not show excessive or non-specific phosphorylation, making this explanation unlikely. Moreover, in a strain expressing normal low levels of Adr1, Ser230 phosphorylation appeared to be present at the same level in wildtype and tpk-null strains. In vivo phosphorylation of Ser230 might involve both Cmk and Tpk, but unregulated Tpk activity did not significantly increase the level of Adr1-pSer230, making this possibility less likely. Therefore, we tentatively conclude that either Ser230 can be phosphorylated by multiple protein kinases that may include PKA and CMK, or its specific kinase is essential, or absent from our deletion collection for another reason. Protein synthesis appeared to be necessary to change the relative level of Adr1-pSer230. This could be interpreted to indicate that an Adr1-specific protein kinase must be synthesized as cells return to repressing growth conditions, or that a protein phosphatase must be synthesized de novo when cells are shifted from repressing to derepressing conditions.
Our results are consistent with the original hypothesis that phosphorylation of Adr1 on Ser230 plays an important role in Adr1 function by altering its ability to regulate downstream genes in a glucose-dependent manner (CHERRY et al. 1989) . Further investigations are required to address this issue and the role of Snf1 in modulating the level of Ser230 phosphorylation.
Regardless of the mechanism, regulating the level of Adr1 phosphorylated on Ser230 appears to be a major function of Snf1 in controlling the expression of Adr1-dependent genes since a nonphosphorylatable Adr1 c could activate both Adr1-dependent genes and a UAS1-containing reporter without Snf1. In contrast, wildtype Adr1 was unable to activate the same genes in the absence of Snf1. This is consistent with our interpretation that pSer230 is a major, albeit indirect, target, by which Snf1 regulates Adr1 activity. The remaining Snf1-dependence when Adr1 c is the activator of genes uniquely dependent on Adr1 could be a function of other Snf1-dependent pathways that are important for activation by Adr1 (VORONKOVA et al. 2006) , or could reflect the requirement for Snf1 in the dephosphorylation of pSer98. This site is adjacent to the DNA binding domain of Adr1, and Ser98 phosphorylation appears to play a repressive role in Adr1 activity by reducing Adr1 promoter binding (KACHEROVSKY et al. 2008) . Like phosphorylation of Ser230, phosphorylation of Ser98 is modulated by Snf1 activity and is reduced in derepressing growth conditions. Whether the two modifications are causally or functionally related is under investigation.
We previously suggested that Adr1 c and Snf1 act on ADH2 expression through separate pathways (DOMBEK et al. 1993 ) based on strong synergism between ADR1 c and deletion of REG1. The data presented here indicate that the synergism is due to Cat8. Thus the primary effect of Snf1 on ADH2 expression in a strain carrying ADR1 c is due to Cat8 whose expression and activity are Snf1-dependent. The enhanced activity of Adr1 c may be related to the observation that it activated genes normally co-dependent on Adr1 and Cat8 in the absence of Cat8.
Eukaryotic promoters generally respond to different environmental signals through the action of multiple transcription factors, leading to combinatorial control of gene expression. Many Adr1-dependent genes are activated by other transcription factors as well. For example, the promoters of genes encoding peroxisomal proteins and the enzymes of ß-oxidation bind both Adr1 and the heterodimeric, oleate-responsive transcription factors Oaf1 and Pip2 (GURVITZ et al. 2001; GURVITZ et al. 2000; SIMON et al. 1991; SIMON et al. 1992; YOUNG et al. 2003) . We are investigating if Adr1 c can compensate for the loss of Oaf1/Pip2 in expression of peroxisomal genes, as it does for the loss of Cat8 at Adr1-and Cat8-dependent promoters.
The finding that Adr1 c can suppress the requirement for Cat8 suggests that in spite of its low protein levels, it has characteristics similar to overexpressed wildtype Adr1, which also escapes Snf1-regulation (DENIS 1987) and also compensates for loss of Cat8 at co-regulated promoters (BIDDICK et al. 2008) . In vitro, by electrophoretic mobility shift assays, Adr1 c does not have exceptional DNA binding activity (TAYLOR and YOUNG 1990) ; however, it may be able to bind promoters efficiently in vivo, where factors like chromatin structure and stabilization by coactivator interaction are proposed to influence Adr1 binding (TACHIBANA et al. 2007; YOUNG et al. 2008) . The wide variety of constitutive Adr1 mutations, such as a complete deletion of amino acids 220-263 and 262-330 (COOK et al. 1994) , suggest that not only the Ser230 phosphorylation site, but the entire region is important for Adr1 regulation. Our results are consistent with a model that mutations in this area affect protein structure, or alter interaction with other factors (COOK et al. 1994) . Although no Adr1-specific repressor has been found in spite of several genetic screens, these findings about Adr1 c suggest a model that can drive further investigation of the novel interaction between Adr1 and Snf1. was analyzed in a similar manner using 100 µg of protein extracted from repressed cells (0 hour derepression) and from cells derepressed for 2, 4, and 22 hours in 0.05% glucose-2% ethanol. Analysis of mRNA isolated from cells derepressed in 0.05% glucose-3% glycerol for 4 hours.
RT-qPCR was performed and analyzed as described in Materials and Methods. Strains were TYY497 (adr1∆SNF1) and TYY498 (adr1∆snf1∆) carrying either wildtype ADR1 (pKD16) or is CMY323, yak1∆ is SGP400, tpk1∆ tpk2∆ tpk3∆ yak1∆ is SGP406, cmk1∆ cmk2∆ cmk3∆ is NKY108. All three strains were transformed with plasmid pNKA1, which has HA-tagged Adr1 expressed from the ADH1 promoter on a multi-copy TRP1 plasmid. Cells were grown in trp -synthetic medium with 5% glucose (repressing conditions). Fifty micrograms of protein extract was analyzed. B. Wildtype is NKY85 and bcy1∆ is NKY111 which are multicopy ADR1. Protein extracts (25 µg wt, 100 µg bcy1∆) were analyzed as described above. The numbers in parentheses indicate the number of replicates analyzed and represent both repressed (complete medium with 5% glucose) and derepressed (2, 4, and 22 hours in complete medium with 0.05% glucose-2% ethanol) cultures.
Supplementary Figure Legends
SUPPLEMENTARY FIGURE 1. Stoichiometry of pSer230 phosphorylation.
Wildtype (wt) is NKY85 (multicopy ADR1); ∆ is TYY204 (adr1∆1::LEU2). Whole cell extracts (WCE) were made from cells grown in repressing conditions. 500 µg of protein were immuneprecipitated (IP) with the antibody shown. After IP 1/5 of the pellet and 1/10 of the supernatant was analyzed by SDS-PAGE on a 6.5% gel. After Western blotting the transferred protein was identified by anti-Adr1 primary and Licor secondary antibodies.
SUPPLEMENTARY FIGURE 2. Snf1-independence of Adr1 c and synergism of Adr1 c and reg1∆. A. ß-galactosidase activity. Reporter gene assays were performed using at least three transformants of strains TYY497 (adr1∆SNF1) and TYY498 (adr1∆snf1∆) carrying either wildtype ADR1 (pKD16) or ADR1-S230A (pKD14). ß-galactosidase activity is reported in Miller units (GUARENTE 1983) . The assays had an average standard deviation of about 20%. R, 5%
glucose; derepressed (DR) values represent 18 hours in low glucose medium. A dilution series of the extracts was used to quantify a four-fold reduction of ADH2 derepression in the snf1 mutant with Adr1 c , compared to no derepression with wildtype Adr1 (data not shown). B. ADH in situ enzyme assays were performed as described in Materials and Methods. Derepression was for six hours. Wildtype (wt) is CKY13 (adr1∆); adr1∆snf1Δ is CKY26, and adr1∆reg1∆ is CKY5, each carrying either wildtype ADR1 (pKD16) or ADR1-S230A (pKD14), respectively. ADHI is the constitutive fermentative isozyme of alcohol dehydrogenase encoded by ADH1. ADHII is the product of the ADH2 gene. Extracts prepared from glucose-grown wild-type cells carrying either pKD16 or pKD14 did not show a band of ADHII activity (data not shown).
SUPPLEMENTARY FIGURE 3. Adr1 c suppresses cat8∆-associated defects in Adr1-dependent gene expression. Cell growth is described in Materials and Methods. A. ß-galactosidase activity.
CAT8 is TYY497; cat8∆ is TYY495 carrying either wild-type ADR1 (pKD16) or ADR1-S230A (pKD14). ß-galactosidase activity is reported in Miller units (GUARENTE 1983) . The assays had an average standard deviation of about 20%. Derepressed (DR) values represent 20 hours in low glucose medium. B. ADH in situ enzyme assays were performed as described in Materials and
Methods. Derepression was for six hours. Wildtype is CKY13 (adr1∆); cat8∆ is CKY23 (adr1∆ cat8∆) each carrying either wildtype ADR1 (pKD16) or ADR1-S230A (pKD14).
